DRAFT
AGENDA
– (revised 6/20/01)
FOOD
AND DRUG ADMINISTRATION
TRANSMISSIBLE
SPONGIFORM ENCEPHALOPATHIES
ADVISORY COMMITTEE
Holiday
Inn
Versailles Ballrooms I & II
Bethesda, Maryland 20814
June 28
& 29, 2001
FIRST
DAY, Thursday, June 28, 2001, OPEN SESSION
8:00
a.m. Administrative
Remarks,
William Freas, PhD., Executive
Secretary
8:10
a.m. Opening
Remarks
David Bolton, PhD., Committee
Chairman
8:20
a.m. Committee
Update:
Summary of DHHS Action Plan on BSE/TSE
Stephen D. Nightengale, M.D.
Executive Secretary, DHHS Advisory Committee on
Blood Safety and Availability
TOPIC 1.
Review of on suitability of blood donors who have lived or traveled in
various countries based on recent information concerning new-variant
Creutzfeldt-Jakob disease (vCJD) and bovine spongiform encephalopathy (BSE)
8:30
a.m. Introduction,
Charge and Questions
FDA TBA
Estimated
Potential Human Exposures to the BSE Agent in Various Countries
8:50
The Geographic BSE Risk Assessment (GBR) Conducted for the
European Commission
Joachim Kreysa, PhD.
Scientific Steering Committee, European Commission
Brussels,
Belgium
9:20
vCJD and Blood Product, Risk Assessment, an EU Policy Position
Professor Jean-Hugues Trouvin
Director,
Directorate for Evaluation of Medicinal Products and Biologicals
French Medicine Agency
TSEAC
AGENDA, June 28, 2001 (continued)
9:35
Mathematical Modeling of Potential Human BSE Exposures in Various BSE
Countries
Cristl Donnely, PhD.
Department
of Epidemiology, University of London
London, UK
BSE Exposure, Risk Reduction
and Projected Effects on Blood Supply
9:55
Potential Exposures to BSE of Canadian Traveler, Possible Blood and
Plasma Donor Deferral
Policies and Projected Effects on the Canadian Blood Supply
Antonio Giulivi, MD.
Associate Director, Bureau of Infectious Diseases,
BloodBorne Pathogens Division
Health Canada
10:05
Break
10:25
Estimated
Effects of Possible Changes in Blood Donor Deferral Policies on Potential
Exposure
to BSE Agent and on the Regional and National Blood Supply in the USA
Allan Williams, PhD.
Director,
Division of Blood Applications
Office
of Blood Research and Review
FDA,
Rockville, MD
10:55
Open Public Hearing
11:35
Committee Discussion, Conclusions, Votes
12:35
Lunch
Topic 2.
Safety of FDA-Regulated Plasma Derivatives Prepared in Establishments
Proposing to Use on the Same Manufacturing Line, Plasma Which Does and Plasma
Which Does Not Comply with Potential European Donor Deferrals for vCJD Risk
Factors
1:30
Introduction, Charge and Questions
Dorothy
Scott, MD., OBRR, FDA
1:40
Scientific Aspects of Decontamination Methods For Transmissible
Spongiform Encephalopathies
Robert
Rohwer, PhD.
Director,
Molecular Neuro-virology Unit, VA Medical Center, Baltimore
TSEAC
AGENDA, June 28, 2001 (continued)
2:25 Industry Presentations:
vCJD Risk
Assessment
Dr. Henry Baron, Senior Director - Prion Research,
Aventis Behring
Considerations
for Facility Cleaning
Jeff Davis, Head
of Research and Development,
ZLB Switzerland
Complexities of Manufacturing
Gordon Busenbark,
Vice President/General Manager
Hyland Immuno Plasma
Impact of vCJD measures re European Donor Deferrals
Christopher Healey, President,
ABRA
3:25
Break
3:
40
Open Public Hearing
4:20
Committee Discussion, Conclusions, Votes
5:30
Adjourn for day 1
FOOD
AND DRUG ADMINISTRATION
TRANSMISSIBLE
SPONGIFORM ENCEPHALOPATHIES
ADVISORY COMMITTEE
SECOND
DAY, Friday, June 29, 2001, OPEN SESSION
TOPIC
3.
Update: Interim results of a
new study on the inactivation of TSE agent by the manufacturing process of
gelatin
8:00
a.m. FDA
Introduction
Yuan Yuan Chiu, Ph.D., CDER, FDA
8:15
European Gelatin Industry, Policy and Measures Ensuring TSE Safety
Michel Schoentjes, Ph.D.
Vice President GME
8:45
Inactivation study: Overview and Results
Robert Rohwer, Ph.D.
9:45
Break
10:00
Open Public Hearing
10:30
FDA Summary
John, Bailey, Ph.D., CFSAN, FDA
10:45
Committee Discussion Committee Discussion
11:45
Adjourn